Targeting the Achilles' shield of TNBC by androgen blockade

Triple-negative breast cancers (TNBC) account for 15-25% of breast carcinomas and are defined by their lack of ER/PR expression, along with the absence of Her2 overexpression or gene amplification. The lack of recognized targets coupled with its aggressive biology makes this subset of breast cancer a subject of intensive effort for new molecular target identification. Our group developed a systematic high-throughput method for profiling therapeutic sensitivity and applied this technology to identify genetic determinants of therapeutic resistance (1). Our studies implicated several cellular pathways associated with radio- and chemo-resistance.